肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Nature：创新IL-2模拟蛋白，有望成为癌症免疫疗法新武器

2019-01-14 佚名 药明康德

IL-2肿瘤免疫细胞因子
关注

日前，美国华盛顿大学的研究人员在《自然》杂志上发表的科学论文表示，该团队构建了一款合成蛋白，它能够模拟IL-2的作用，而且可以避免与IL-2相关的毒副作用，这一合成蛋白有望成为有力的癌症免疫疗法。

日前，美国华盛顿大学的研究人员在《自然》杂志上发表的科学论文表示，该团队构建了一款合成蛋白，它能够模拟IL-2的作用，而且可以避免与IL-2相关的毒副作用，这一合成蛋白有望成为有力的癌症免疫疗法。

IL-2是一种中枢免疫细胞因子，它激发的信号通路在癌症治疗方面表现很大的潜力，但是IL-2的癌症治疗潜力目前受到IL-2毒副作用的限制。因为在细胞中存在两种不同类型的IL-2受体。由CD122和CD132构成的IL-2受体与IL-2相结合会提高CD8+T细胞和天然杀伤细胞的增殖和激活，从而提高癌症免疫疗法的效果。然而IL-2倾向于与包含CD25的受体相结合，这些受体表达在调节性T细胞上，激活这些受体会导致免疫抑制性细胞的增生，并且会造成可能致命的肺水肿、低血压和毛细血管渗漏症。

为了在保持IL-2抗癌疗效的同时降低它的副作用，华盛顿大学的研究团队使用计算机模型，从IL-2和IL-15中提取结构元件构建了一个名为NEO-201的合成蛋白。这种合成蛋白能够与CD122和CD132构成的受体结合，但是不会与CD25结合。而且，NEO-201与CD122和CD132构成的受体复合体的亲和力高于天然的IL-2细胞因子，它同时非常稳定，在高温下也不会失去亲和力。

在黑色素瘤的小鼠模型中，NEO-201加抗TYRP1单克隆抗体与IL-2加同样抗体相比，能够在降低肿瘤生长的同时减少细胞毒性。NEO-201同时能够提高肿瘤中CD8+/调节性T细胞的比例，这一比例的升高已经被证明与更有效的抗癌免疫反应相关。

原始出处：

Daniel-Adriano Silva，et al.De novo design of potent and selective mimics of IL-2 and IL-15.Nature.09 January 2019

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883533, encodeId=27d41883533e8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 24 04:38:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358276, encodeId=5bb33582e656, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 16 08:15:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285701, encodeId=480f1285e01b9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358136, encodeId=a84735813690, content=施一公也发了这个期刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:42:16 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-09-24 liye789132251

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1883533, encodeId=27d41883533e8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 24 04:38:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358276, encodeId=5bb33582e656, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 16 08:15:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285701, encodeId=480f1285e01b9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358136, encodeId=a84735813690, content=施一公也发了这个期刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:42:16 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-16 kafei

    学习了谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1883533, encodeId=27d41883533e8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 24 04:38:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358276, encodeId=5bb33582e656, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 16 08:15:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285701, encodeId=480f1285e01b9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358136, encodeId=a84735813690, content=施一公也发了这个期刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:42:16 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-16 lilianxiang

    #创新#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1883533, encodeId=27d41883533e8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 24 04:38:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358276, encodeId=5bb33582e656, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 16 08:15:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285701, encodeId=480f1285e01b9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358136, encodeId=a84735813690, content=施一公也发了这个期刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:42:16 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-16 heli0118

    #IL-2#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1883533, encodeId=27d41883533e8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 24 04:38:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358276, encodeId=5bb33582e656, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Jan 16 08:15:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285701, encodeId=480f1285e01b9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jan 16 04:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358136, encodeId=a84735813690, content=施一公也发了这个期刊, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:42:16 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 1405898496_61595865

    施一公也发了这个期刊

    0

相关资讯

Sci Signal：IL-2信号通路对自身免疫疾病的影响

调节性T细胞 (regulatory T cells， Treg) 能够抑制对自体产生反应的效应T细胞，从而防止诸如1型糖尿病这类自身免疫疾病的产生。而白细胞介素-2 (interleukin-2， IL-2) 对Treg细胞不同亚型的发育和在体内的动态平衡非常重要。

J Gerontol A Biol Sci Med Sci：IL-6水平升高可导致老人谵妄的发生？

对术后患者的研究表明，炎症因子水平的升高与患者谵妄的发生相关。谵妄是一种严重的精神错乱，往往发生在老年人术后或者身患重大疾病的时候。目前，由贝斯以色列女执事医疗中心（BIDMC）所进行的一项新的研究证实，炎症（身体遭受有害刺激时机体的一种保护性免疫反应）在谵妄的发生中起重要作用，该研究成果发表于The Journals of Gerontology, Series A: Biological Sc

Diabetes：IL-2受体在1型糖尿病中发挥中枢性作用

近日，一项发表在Diabetes杂志上的一则研究"Central role for interleukin-2 in type 1 diabetes"证实IL-2在1型糖尿病中的关键性作用。 1型糖尿病临床表现为显著高血糖症，由进展性免疫介导的胰岛β细胞损伤及相关代谢功能障碍引起。如今遗传与免疫联合研究突出白细胞介素－2 (IL-2) 受体及其下游信号传导通路缺陷1型糖尿病发病机制中的中枢缺